TI
ACHN

Trexquant Investment’s Achillion Pharmaceuticals ACHN Stock Holding History

Trexquant Investment’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-11,449
Closed -$93K – 1220
2016
Q3 		$93K Sell
11,449
-4,992
-30% -$42.4K 0.02% 694
2016
Q2 		$128K Buy
+16,441
New +$141K 0.02% 813
2015
Q2 		– Sell
-143,210
Closed -$1.41M – 1347
2015
Q1 		$1.41M Buy
+143,210
New +$1.79M 0.14% 229

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Trexquant Investment's ACHN Position: Q4 2016 in Review

Trexquant Investment sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 11,449 shares — an estimated $93K sold.

Trexquant Investment first reported a position in ACHN in Q1 2015 and held it in 3 quarters. The position peaked at $1.41M in Q1 2015. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • Trexquant Investment reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Trexquant Investment sold 11,449 Achillion Pharmaceuticals shares in Q4 2016, an estimated $93K.
  • Trexquant Investment first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Trexquant Investment's Achillion Pharmaceuticals position peaked at $1.41M in Q1 2015.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Trexquant Investment's 13F filing for Q4 2016, filed 10 Feb 2017.